Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.

Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome ...

BMO Capital lowered the firm’s price target on Neurogene (NGNE) to $45 from $60 and keeps an Outperform rating on the shares. The shares are ...

Failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells ...

Baird lowered the firm’s price target on Neurogene (NGNE) to $46 from $72 and keeps an Outperform rating on the shares. The firm updated its ...

Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that ...

Talks with the FDA haven’t gone according to plan. Seeking a streamlined pathway, Neurogene submitted a Regenerative Medicine ...

Neurogene (NASDAQ:NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy ...

At Neurogene, the developer of a gene therapy for Rett syndrome, expediency seems to be the priority, @adamfeuerstein writes.

Neurogene is proceeding with a scaled-back study of its proposed NGN-401 gene therapy for the rare genetic neurological disorder Rett syndrome after a serious adverse event left a study participant in ...

In an update posted today, Neurogene said that the "emerging treatment-related serious adverse event (SAE)" was a case of systemic hyperinflammatory syndrome, a rare and life-threatening immune ...

Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome treatment.